Effettuare il login Iscriviti gratis

IMV Q/Q di EPS

Cos'è Q/Q di EPS di IMV?

Q/Q di EPS di IMV, Inc. è 831.25%

Qual è la definizione di Q/Q di EPS?



Il tasso di crescita trimestrale dell'utile, trimestre su trimestre , è l'aumento di EPS di un'azienda negli ultimi 4 trimestri rispetto alla performance dei precedenti 4 trimestri.

The earnings per share growth rate is an important factor for judging a company's value. EPS growth rate gives a good picture of the rate at which the company has grown its profitability in respect to the total number of shares. Comparing EPS history with stock price history helps determine the most likely future direction of the stock price.

Earnings per share is the monetary value of earnings per outstanding share of common stock for a company. The EPS is usually calculated as profit without preferred dividends divided by weighted average of common stock shares over the past twelve months.

Q/Q di EPS di aziende nel Health Care settore su TSX rispetto a IMV

Cosa fa IMV?

IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and microsatellite instability high tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.

Aziende con q/q di eps simili a IMV